Cite
Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction.
MLA
Lampl, Christian, et al. “Efficacy and Quality‐of‐life Improvements with Fremanezumab Treatment in Patients with Difficult‐to‐treat Migraine with Associated Neurological Dysfunction.” European Journal of Neurology, vol. 29, no. 7, July 2022, pp. 2129–37. EBSCOhost, https://doi.org/10.1111/ene.15328.
APA
Lampl, C., Rapoport, A. M., Cohen, J. M., Barash, S., Ramirez Campos, V., Seminerio, M. J., Ning, X., & Silberstein, S. D. (2022). Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction. European Journal of Neurology, 29(7), 2129–2137. https://doi.org/10.1111/ene.15328
Chicago
Lampl, Christian, Alan M. Rapoport, Joshua M. Cohen, Steve Barash, Verena Ramirez Campos, Michael J. Seminerio, Xiaoping Ning, and Stephen D. Silberstein. 2022. “Efficacy and Quality‐of‐life Improvements with Fremanezumab Treatment in Patients with Difficult‐to‐treat Migraine with Associated Neurological Dysfunction.” European Journal of Neurology 29 (7): 2129–37. doi:10.1111/ene.15328.